US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Health Innovation Active ETF

33.80

+0.02710.08%

Post-market: 33.77-0.0271-0.08%16:10 EDT

Volume:222

Turnover:8K

Market Cap:13.52M

PE:- -

High:33.80

Open:33.77

Low:33.80

Close:33.77

52wk High:34.98

52wk Low:27.25

Shares:400.00K

Float Shares:400.00K

Volume Ratio:0.14

T/O Rate:0.06%

Dividend:0.08

Dividend Rate:0.24%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Edwards Lifesciences (EW) Receives a Buy from RBC Capital

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Biogen Inc. Stock Underperforms Friday When Compared to Competitors

Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure

Biogen Says Litifilimab Safety Profile Consistent with no New Safety Signals Identified

Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says

MT Newswires Live

Biogen's Experimental Lupus Drug Shows Benefit Against Skin Symptoms

Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook

Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study

Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52

THOMSON REUTERS

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~

THOMSON REUTERS

Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period

THOMSON REUTERS

Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52

THOMSON REUTERS

Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study

Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study

J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112

THOMSON REUTERS

Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~

THOMSON REUTERS

J&J - 60% Scalp Psoriasis, 89% Genital Psoriasis Patients Achieve Complete Clearance at Week 112

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/BMED/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.7958,"timestamp":1790971200000,"preClose":33.7687,"halted":0,"volume":222,"hourTrading":{"tag":"盘后","latestPrice":33.7687,"preClose":33.7958,"latestTime":"16:10 EDT","volume":6,"amount":202.7748,"timestamp":1790971804491,"change":-0.0271,"changeRate":-0.000802,"amplitude":0},"delay":0,"changeRate":0.0008025183083742411,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"Market Closed","change":0.0271,"latestTime":"10-02 16:00:00 EDT","open":33.7687,"high":33.7958,"low":33.7958,"amount":7529,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":33.7687,"sharesOutstanding":360000,"nav":33.765684,"aum":13506273.6,"dividendRate":0.002361,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.7687,"preClose":33.7958,"latestTime":"16:10 EDT","volume":6,"amount":202.7748,"timestamp":1790971804491,"change":-0.0271,"changeRate":-0.000802,"amplitude":0},"volumeRatio":0.13654815922563465,"impliedVol":0.2698,"impliedVolPercentile":0.7331},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.13654815922563465,"shares":400000,"dividePrice":0.0798,"high":33.7958,"amplitude":0,"preClose":33.7687,"low":33.7958,"week52Low":27.25,"pbRate":"--","week52High":34.98,"institutionHeld":0,"latestPrice":33.7958,"eps":0,"divideRate":0.002361,"volume":222,"delay":0,"ttmEps":0,"open":33.7687,"prevYearClose":30.32,"prevWeekClose":34.7637,"prevMonthClose":34.561,"prevQuarterClose":34.561,"fiveDayClose":34.7637,"twentyDayClose":34.42,"sixtyDayClose":31.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2672742233","title":"Edwards Lifesciences (EW) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2672742233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672742233?lang=en_us&edition=fundamental","pubTime":"2026-10-03 09:46","pubTimestamp":1790992018,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Kendall Au maintained a Buy rating on Edwards Lifesciences on October 1 and set a price target of $110.00. The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/edwards-lifesciences-ew-receives-a-buy-from-rbc-capital-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/edwards-lifesciences-ew-receives-a-buy-from-rbc-capital-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","IE00BN0W2W23.USD","SG9999001176.SGD","LU0029864427.USD","AGNG","LU1267930573.SGD","LU0708994859.HKD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IHI","BK4585","LU0128525929.USD","IE00BFXG0V08.USD","LU0289739699.SGD","BMED","EW","GSIB","LU0345774631.USD","IE00BYQQ9H92.USD","LU0823416689.USD","LU0310800379.SGD","BK4207","SG9999001176.USD","BK4504","BK4588","LU0345774391.USD","BK4567","BK4082","SG9999013999.USD","SGXZ57979304.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672999741","title":"Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2672999741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672999741?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:30","pubTimestamp":1790976600,"startTime":"0","endTime":"0","summary":"DJ Perrigo Co. PLC Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Perrigo Co. PLC  advanced 1.71% to $14.26 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.73% to 7,722.72 and the Dow Jones Industrial Average  rising 0.49% to 51,176.96.The stock's rise snapped a four-day losing streak.Perrigo Co. PLC closed 37.04% below its 52-week high of $22.65, which the company reached on October 3rd.The stock outperformed some of its competitors Friday, as Johnson & Johnson  fell 1.02% to $256.03, Procter & Gamble Co.  rose 0.67% to $144.91, and Abbott Laboratories  rose 0.84% to $97.50.Trading volume  remained 711,062 below its 50-day average volume of 2.9 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 2, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","IE000SO60NU8.SGD","FHLC","BK4558","LU1585245621.USD","PG","LU0096364046.USD","RXL","LU1162221912.USD","FSTA","PRGO","BK4533","IYH","LU1066051498.USD","IXJ","LU1280957306.USD","TMED","TRUO","XLP","GDOC","PJP","TRUH","LU2211815571.USD","UGE","SGXZ57979304.SGD","LU1228905037.USD","LU1059921491.USD","IE00B19Z3B42.SGD","BK4018","LU0070217475.USD","LU1057294990.SGD","LU1929549753.HKD","VHT","LU0320765489.SGD","XLV","BMED","FTXH","MEDX","LU1261432733.SGD","LU1196500208.SGD","LU0820562030.AUD","IHE","IHI","LU0661504455.SGD","JDOC","JNJ","BK4567","ABT","LU1496350502.SGD","SGXZ23171101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749086","title":"Biogen Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749086","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749086?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:56","pubTimestamp":1790974560,"startTime":"0","endTime":"0","summary":"DJ Biogen Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Biogen Inc.  slid 1.32% to $219.88 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.73% to 7,722.72 and the Dow Jones Industrial Average  rising 0.49% to 51,176.96.This was the stock's fourth consecutive day of losses.Biogen Inc. closed 4.60% short of its 52-week high of $230.49, which the company achieved on September 28th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  fell 1.02% to $256.03, Pfizer Inc.  fell 1.14% to $27.80, and AbbVie Inc.  rose 1.11% to $262.82.Trading volume  remained 180,740 below its 50-day average volume of 954,757.Data source: Dow Jones Market Data, FactSet. Data compiled October 2, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BMED","BK4533","BK4139","PBE","LU0320765992.SGD","BIIB","LU0889565916.HKD","LU0109394709.USD","IE00B894F039.SGD","BK4585","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749473","title":"Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749473","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749473?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:42","pubTimestamp":1790973757,"startTime":"0","endTime":"0","summary":"Gilead CEO Daniel O’Day disposes of USD 2,216,507.50 in common sharesGilead Sciences Chairman and CEO Daniel Patrick O’Day sold 15,000 common shares on Oct. 1, 2026.Sales were priced at USD 147.719 an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL7B1xgm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Gilead CEO Daniel O’Day Disposes of USD 2,216,507.50 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BSNM7G36.USD","LU1778281490.HKD","SG9999015978.USD","BK4550","IE00B19Z3B42.SGD","LU0859254822.USD","LU2468319806.SGD","IBBQ","LU0861579265.USD","BK4585","IE00BKVL7J92.USD","LU0965509101.SGD","LU1934455277.USD","LU1934455863.HKD","LU2087621335.USD","BK4588","BK4578","LU2089984988.USD","TBXU","BIB","LU0320765992.SGD","LU0965508806.USD","LU1066051498.USD","MEDI","LU0058720904.USD","LU1585245621.USD","LU0889565916.HKD","BK4532","BBH","IE00B19Z3581.USD","IBB","LU1023059063.AUD","LU1430594728.SGD","LU2357627491.SGD","LU0882574055.USD","GILD","LU1037948897.HKD","LU1934455194.USD","TMED","LU1674673428.USD","LU1571399168.USD","LU0289739699.SGD","LU2324357040.USD","LU0823416689.USD","SG9999015986.USD","BMED","LU0109394709.USD","IE0002270589.USD","LU0234570918.USD","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749136","title":"Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749136","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749136?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:35","pubTimestamp":1790973300,"startTime":"0","endTime":"0","summary":"DJ Gilead Sciences Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slid 1.87% to $144.74 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.73% to 7,722.72 and the Dow Jones Industrial Average  rising 0.49% to 51,176.96.This was the stock's fourth consecutive day of losses.Gilead Sciences Inc. closed 7.98% below its 52-week high of $157.29, which the company achieved on February 11th.The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson  fell 1.02% to $256.03, Pfizer Inc.  fell 1.14% to $27.80, and Abbott Laboratories  rose 0.84% to $97.50.Trading volume  remained 1.3 million below its 50-day average volume of 6.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled October 2, 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU1585245621.USD","IE00BSNM7G36.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","LU0320765992.SGD","LU1037948897.HKD","LU1057294990.SGD","LU1934455863.HKD","BK4583","LU2357627491.SGD","LU1066053197.SGD","SG9999015986.USD","TMED","LU0965509283.SGD","LU0965509101.SGD","SG9999015952.SGD","LU0861579265.USD","LU0965508806.USD","LU0889565916.HKD","LU2468319806.SGD","LU0114720955.EUR","BIB","BK4532","BK4585","LU0965509010.AUD","LU1430594728.SGD","LU1778281490.HKD","LU1674673691.USD","LU0109394709.USD","SG9999015945.SGD","BK4578","LU0289739699.SGD","MEDI","BK4566","LU1061106388.HKD","TBXU","LU1571399168.USD","LU2324357040.USD","IE00B7SZLL34.SGD","BMED","BBH","IE00B3T34201.USD","LU1023059063.AUD","IE00B19Z3581.USD","IBB","LU0859254822.USD","SG9999015978.USD","LU1839511570.USD","LU0823416689.USD","GILD","BK4139","IE00BKVL7J92.USD","LU0234570918.USD","LU1037948541.HKD","LU1674673428.USD","LU2087621335.USD","IBBQ","LU1066051498.USD","IE00B19Z3B42.SGD","LU2112291526.USD","BK4588","IE0002270589.USD","LU2089984988.USD","LU1934455277.USD","BK4550","LU0122379950.USD","LU1934455194.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672469877","title":"Why Medtronic's $4 Billion MiniMed Exchange Offer is Losing Its Allure","url":"https://stock-news.laohu8.com/highlight/detail?id=2672469877","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672469877?lang=en_us&edition=fundamental","pubTime":"2026-10-03 03:27","pubTimestamp":1790969220,"startTime":"0","endTime":"0","summary":"Medtronic's $4 billion exchange offer for its shares of MiniMed Group is a lot less attractive now that MiniMed's stock has dropped since the offer was unveiled a couple of weeks ago.That could reduce","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU0029864427.USD","VHT","RSPS","IE00BDGV0183.EUR","LU1244550221.USD","MEDX","IXJ","JDOC","SG9999002224.SGD","RXL","LU0098860793.USD","JNJ","LU2505996509.AUD","BMED","LU0234572021.USD","LU2111349929.HKD","DXCM","MMED","IHE","LU1116320901.HKD","LU2089984988.USD","LU0976567544.SGD","IE00B2B36J28.USD","IE00B42XCP33.USD","IE00B1BXHZ80.USD","EKG","LU2896262040.SGD","GLAM","IE00BLSP4239.USD","LU1145028129.USD","LU1074936037.SGD","SG9999002232.USD","MDT","IE000M9KFDE8.USD","LU2129689431.USD","LU1989764748.USD","GDOC","TRUH","XLV","HEAL","IE00BJT1NW94.SGD","IE00BZ1G4Q59.USD","LU1043141396.HKD","KVUE","FTXH","IYH","PJP","LU0354030511.USD","LU0210536198.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672301745","title":"Biogen Says Litifilimab Safety Profile Consistent with no New Safety Signals Identified","url":"https://stock-news.laohu8.com/highlight/detail?id=2672301745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672301745?lang=en_us&edition=fundamental","pubTime":"2026-10-03 01:25","pubTimestamp":1790961920,"startTime":"0","endTime":"0","summary":"BRIEF-Biogen Says Litifilimab Safety Profile Consistent With No New Safety Signals IdentifiedOct 2 (Reuters)-Biogen Inc.BIIB.O:BIOGEN’S LITIFILIMAB DEMONSTRATES RAPID AND DURABLE EFFICACY IN NEW 52-WE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IE00B894F039.SGD","LU0889565916.HKD","BK4532","BK4585","BK4588","LU0234570918.USD","LU0320765992.SGD","LU0109394709.USD","IE00B19Z9Z06.USD","PBE","BK4533","BK4139","BIIB","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672034743","title":"Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2672034743","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672034743?lang=en_us&edition=fundamental","pubTime":"2026-10-03 01:05","pubTimestamp":1790960723,"startTime":"0","endTime":"0","summary":"Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as Gilead Sciences' (GILD) anito-cel approaches a potential approval and Johnson & Johnson's (JNJ) Tec-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0545039389.USD","LU1057294990.SGD","MEDI","LU1585245621.USD","LU2129689605.HKD","LU0889566641.SGD","BBH","CANC","LU0426417589.USD","BK4550","LU0859254822.USD","LU1261432733.SGD","MEMS","LU0345770308.USD","JDOC","IBBQ","IXJ","XBI","MEDX","JNJ","RXL","GILD","BMED","LU1162221912.USD","BIB","TRUH","IYH","LABU","XLV","LU0545562505.USD","IE00BLSP4239.USD","IE00B42XCP33.USD","PJP","IHE","BK4504","FTXH","LEGN","TBXU","LU0320765992.SGD","TMED","FHLC","IBB","VHT","IE0034235303.USD","IE00BKVL7J92.USD","LU1221951046.USD","SG9999001440.SGD","GDOC","LU0345769631.USD","IE00BLSP4452.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672743907","title":"Biogen's Experimental Lupus Drug Shows Benefit Against Skin Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2672743907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672743907?lang=en_us&edition=fundamental","pubTime":"2026-10-03 00:39","pubTimestamp":1790959165,"startTime":"0","endTime":"0","summary":"Biogen's experimental lupus drug shows benefit against skin symptomsOct 2 (Reuters)-BiogenBIIB.Osaid on Friday its experimental drug showed durable improvement in skin symptoms among patients with a t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nL4N45O11Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BMED","BK4139","BK4532","BK4533","BK4585","IE00B894F039.SGD","LU0234570918.USD","LU0889565916.HKD","LU0320765992.SGD","PBE","BK4588","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672743138","title":"Biogen’s Salanersen Trial Strengthens Its SMA Pipeline Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2672743138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672743138?lang=en_us&edition=fundamental","pubTime":"2026-10-03 00:31","pubTimestamp":1790958685,"startTime":"0","endTime":"0","summary":"Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is running a Phase 3 study of salanersen (BIIB115) in p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biogens-salanersen-trial-strengthens-its-sma-pipeline-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biogens-salanersen-trial-strengthens-its-sma-pipeline-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","BK4532","BIIB","BK4139","BK4588","LU0109394709.USD","LU0234570918.USD","BK4533","BK4585","IE00B19Z9P08.USD","LU0320765992.SGD","IE00B19Z9Z06.USD","LU0889565916.HKD","PBE","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672748656","title":"Biogen Says Litifilimab Posts Sustained Skin Clearance in 52-Week Phase 2 Cutaneous Lupus Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2672748656","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672748656?lang=en_us&edition=fundamental","pubTime":"2026-10-02 23:20","pubTimestamp":1790954443,"startTime":"0","endTime":"0","summary":"Biogen says litifilimab posts sustained skin clearance in 52-week Phase 2 cutaneous lupus studyBiogen reported 52-week Phase 2 AMETHYST data for litifilimab in cutaneous lupus erythematosus, previousl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL57zG2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0234570918.USD","BK4585","LU0889565916.HKD","SG9999014021.USD","BK4533","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210149790.SGD","SG9999014005.SGD","SG9999014039.USD","IE00BQXX3C00.GBP","IE00BQXX3F31.USD","LU2095319765.USD","LU0109394709.USD","IE00BGHQF748.EUR","IE00B894F039.SGD","IE00B64PRP62.GBP","IE00B19Z9P08.USD","LU2210150020.SGD","IE00B19Z9Z06.USD","NDAQ","BCDF","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4139","IE00B3QW5Z07.USD","PBE","IE00BKPKM429.USD","BK4532","LU0320765992.SGD","BK4112","BMED","BIIB","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672748638","title":"Biogen - 28.8% of Participants Achieve 70% or Greater Reduction in Clasi a at Week 52","url":"https://stock-news.laohu8.com/highlight/detail?id=2672748638","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672748638?lang=en_us&edition=fundamental","pubTime":"2026-10-02 23:20","pubTimestamp":1790954408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0A5:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PBE","LU0234570918.USD","IE00B19Z9Z06.USD","BK4533","BIIB","LU0889565916.HKD","BK4585","BMED","BK4588","IE00B19Z9P08.USD","LU0109394709.USD","BK4139","LU0320765992.SGD","IE00B894F039.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672748636","title":"Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 Amethyst Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus~","url":"https://stock-news.laohu8.com/highlight/detail?id=2672748636","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672748636?lang=en_us&edition=fundamental","pubTime":"2026-10-02 23:20","pubTimestamp":1790954408,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BIIB","LU0234570918.USD","LU0109394709.USD","BK4139","IE00B19Z9P08.USD","BK4533","BK4585","BMED","IE00B894F039.SGD","LU0889565916.HKD","PBE","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672687748","title":"Biogen - Serious Adverse Events Occurred in 3.4% of Participants During 52-Week Treatment Period","url":"https://stock-news.laohu8.com/highlight/detail?id=2672687748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672687748?lang=en_us&edition=fundamental","pubTime":"2026-10-02 23:20","pubTimestamp":1790954408,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0A5:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMED","BK4532","IE00B19Z9Z06.USD","BK4533","IE00B19Z9P08.USD","PBE","BK4139","LU0889565916.HKD","LU0109394709.USD","BK4588","BK4585","LU0320765992.SGD","LU0234570918.USD","IE00B894F039.SGD","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672574863","title":"Biogen - 33.7% of Crossover Participants Report Clear or Almost Clear Skin at Week 52","url":"https://stock-news.laohu8.com/highlight/detail?id=2672574863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672574863?lang=en_us&edition=fundamental","pubTime":"2026-10-02 23:20","pubTimestamp":1790954408,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O0A5:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0234570918.USD","LU0889565916.HKD","BK4533","IE00B19Z9P08.USD","BMED","BK4532","BIIB","BK4139","BK4588","IE00B894F039.SGD","IE00B19Z9Z06.USD","PBE","LU0109394709.USD","BK4585","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672716311","title":"Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study","url":"https://stock-news.laohu8.com/highlight/detail?id=2672716311","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672716311?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:05","pubTimestamp":1790935529,"startTime":"0","endTime":"0","summary":"Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTAL study demonstrating the positive impact of ICOTYDE on high-impact plaqu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-two-year-data-from-phase-3-iconic-total-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/johnson-johnson-announces-two-year-data-from-phase-3-iconic-total-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PJP","IE00BJT1NW94.SGD","BK4581","RXL","BK4534","VHT","IE000M9KFDE8.USD","LU0466842654.USD","IXJ","LU2417539215.USD","TRUH","MEDX","LU0234570918.USD","BK4592","LU0994945656.USD","LU1551013342.USD","LU1496350502.SGD","IYH","LU2471134952.CNY","IE000WAW04H5.SGD","LU2430703251.USD","IE0002270589.USD","LU0640476718.USD","FHLC","IE00B2B36J28.USD","BK4588","LU2236285917.USD","LU2468319806.SGD","IE00B19Z3B42.SGD","LU1732800096.USD","SG9999002224.SGD","IE00BDGV0183.EUR","LU1551013425.SGD","IHE","GDOC","FTXH","LU1066053197.SGD","LU0162691827.USD","XLV","LU2505996509.AUD","BMED","JNJ","LU0426412945.USD","JDOC","SGXZ57979304.SGD","LU0203345920.USD","LU2896262040.SGD","LU1043141396.HKD","LU0738911758.USD","SG9999013999.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672715109","title":"Johnson & Johnson Says Icotyde Sustains Psoriasis Skin Clearance Through 2 Years in Phase 3 Iconic-TOTAL Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2672715109","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672715109?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:01","pubTimestamp":1790935267,"startTime":"0","endTime":"0","summary":"Johnson & Johnson says ICOTYDE sustains psoriasis skin clearance through 2 years in Phase 3 ICONIC-TOTAL studyJohnson & Johnson disclosed new two-year Phase 3 ICONIC-TOTAL results for ICOTYDE (icotrok","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL8bWfkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0072461881.USD","LU1674673691.USD","LU1732800096.USD","FHLC","BMED","LU2129689605.HKD","XLV","IE0034235303.USD","MEDX","LU1066051225.USD","BK4592","IYH","VHT","LU2456880835.USD","LU0545039389.USD","JDOC","RXL","LU1629891620.HKD","LU0234572021.USD","LU0738911758.USD","IE00BBT3K403.USD","TRUH","LU0162691827.USD","LU0820561818.USD","SG9999001440.SGD","LU1061106388.HKD","LU1066051811.HKD","IE00B4R5TH58.HKD","IE0009355771.USD","JNJ","IXJ","SG9999002224.SGD","LU2347655156.SGD","LU0994945656.USD","IE00BSNM7G36.USD","IE00BJT1NW94.SGD","LU1430594728.SGD","LU2896262040.SGD","IHE","SG9999001176.USD","IE00BLSP4452.SGD","LU1043141396.HKD","GDOC","IE0000B7K699.USD","LU2430703251.USD","LU0426412945.USD","LU1043141123.HKD","FTXH","LU2417539215.USD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672971590","title":"J&J - Icotyde-Treated Patients Show 70% Clear or Almost Clear Skin at Week 112","url":"https://stock-news.laohu8.com/highlight/detail?id=2672971590","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672971590?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:00","pubTimestamp":1790935203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O09I:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0426417589.USD","LU0795875169.SGD","IE00B4R5TH58.HKD","MEDX","LU1674673691.USD","BMED","LU2129689605.HKD","IHE","LU2471134879.HKD","IE00BLSP4452.SGD","LU0820561909.HKD","GDOC","IE00BFTCPJ56.SGD","LU0820562030.AUD","LU0882574055.USD","LU1551013342.USD","IYH","LU0072461881.USD","LU1121112475.USD","LU0320765646.SGD","FTXH","LU0162691827.USD","LU0426412945.USD","FHLC","LU0912757837.SGD","LU1496350502.SGD","LU1061106388.HKD","LU1551013425.SGD","BK4568","LU1989771016.USD","LU2347655156.SGD","LU0057025933.USD","PJP","JDOC","JNJ","XLV","LU1162221912.USD","LU1066051498.USD","LU1935042991.SGD","TRUH","SGXZ80539844.SGD","RXL","IE0001KFT4U8.USD","IE00B19Z3581.USD","VHT","IXJ","BK4581","LU0234572021.USD","LU2592432038.USD","LU1221951046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672900715","title":"Johnson & Johnson Announces New Icotyde® (Icotrokinra) Data in Difficult-to-Treat Plaque Psoriasis with Proven Durability Through 2-Years, Affirming Its Use as a Powerful First Line Systemic Therapy~","url":"https://stock-news.laohu8.com/highlight/detail?id=2672900715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672900715?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:00","pubTimestamp":1790935203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O09I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MEDX","LU1003077747.HKD","LU0820561909.HKD","IHE","LU0203345920.USD","LU1267930813.SGD","IE00BDGV0183.EUR","FTXH","IXJ","IE00BKVL7J92.USD","JDOC","BMED","IE00BGHQF631.EUR","LU0234570918.USD","GDOC","LU0792757196.USD","LU0889566641.SGD","TRUH","IE00BSNM7G36.USD","LU0882574055.USD","LU0203347892.USD","IE00BVYPNW00.USD","LU0511384066.AUD","BK4550","LU2750360641.GBP","VHT","BK4568","BK4581","IYH","LU0070217475.USD","LU0795875086.SGD","LU1430594728.SGD","FHLC","LU0432979614.USD","PJP","LU1066053197.SGD","RXL","LU1551013342.USD","LU0820562030.AUD","LU0472753341.HKD","LU1989771016.USD","XLV","LU1674673691.USD","JNJ","LU1228905037.USD","LU0122379950.USD","LU1221951129.SGD","LU1066051225.USD","IE0009355771.USD","IE00BVYPNV92.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672715972","title":"J&J - 60% Scalp Psoriasis, 89% Genital Psoriasis Patients Achieve Complete Clearance at Week 112","url":"https://stock-news.laohu8.com/highlight/detail?id=2672715972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672715972?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:00","pubTimestamp":1790935203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nFWN45O09I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0072461881.USD","LU1551013425.SGD","LU0162691827.USD","LU0203347892.USD","LU2129689514.USD","IE00B19Z3B42.SGD","LU2456880835.USD","LU0545562505.USD","LU1221951129.SGD","VHT","TRUH","LU1506573853.SGD","LU1043141123.HKD","JDOC","LU1267930813.SGD","LU2505996681.GBP","SG9999002232.USD","BMED","LU0345769128.USD","IHE","LU1145028129.USD","LU0820562030.AUD","FHLC","IE00BN8TJ469.HKD","LU1732800096.USD","LU2471134879.HKD","GDOC","BK4581","LU0964807845.USD","JNJ","LU1914381329.SGD","LU1983299246.USD","LU0210528500.USD","IYH","RXL","IE000F7OJYX1.SGD","FTXH","IE00BFTCPJ56.SGD","IXJ","XLV","IE00B1BXHZ80.USD","PJP","BK4588","LU1074936037.SGD","LU0345770993.USD","IE000BZT7R73.USD","MEDX","LU0882574055.USD","IE000MB6IJN5.SGD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":1,"totalSize":224,"code":"91000000","status":"200"}]}}